- Home
- CELH vs ROIV Comparison
CELH vs ROIV Comparison
Compare CELH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | ROIV |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 20.7B |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CELH | ROIV |
|---|---|---|
| Price | $36.45 | $26.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $66.50 | $27.56 |
| AVG Volume (30 Days) | ★ 5.5M | 4.5M |
| Earning Date | 05-05-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,318,014,000.00 | $29,053,000.00 |
| Revenue This Year | $37.68 | N/A |
| Revenue Next Year | $10.02 | $594.84 |
| P/E Ratio | $166.52 | ★ N/A |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $32.36 | $8.73 |
| 52 Week High | $66.74 | $30.33 |
Technical Indicators
Market Signals| Indicator | CELH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 45.05 |
| Support Level | $34.10 | $26.94 |
| Resistance Level | $47.00 | $27.94 |
| Average True Range (ATR) | 2.21 | 0.90 |
| MACD | -0.66 | -0.39 |
| Stochastic Oscillator | 7.84 | 9.63 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.